PALO ALTO, Calif., Oct. 26 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today that Telintra (Ezatiostat HCl), the company's lead therapeutic product candidate, has been selected by Windhover Information and its advisors as one of "The Top 10 Most Interesting Oncology Projects to Watch." Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology, and medical device industries. The company has been invited to present at Windhover's Therapeutic Area Partnerships conference on November 3, 2010 in Boston, MA.
Telintra is among the first therapeutic products in a novel class of small-molecule drug candidates which inhibit the enzyme glutathione S-transferase P1-1 for the treatment of malignancies, including myelodysplastic syndrome (MDS) and hematologic diseases characterized by cytopenias. Telintra may induce apoptosis, or cellular death, in leukemia cells and cause differentiation and proliferation of normal bone marrow blood cell precursors, leading to an increase in platelets, red cells, and white cells.
Telintra has recently completed a positive Phase 2 study in patients with Low to Intermediate Risk-1 MDS and has shown evidence of clinical activity and tolerability in multiple Phase 1 and Phase 2 clinical studies.
About MDS and Telintra
The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis (blood cell production) involving one or more cell lineages (red blood cells, white blood cells, or platelets) and a variable risk of transformation to acute myeloid leukemia (AML). MDS becomes more common with age. It is estimated that MDS affects approximately 300,000 people worldwide. According to the American Cancer Society, 10,000–20,000 new cases of MDS are dia
|SOURCE Telik, Inc.|
Copyright©2010 PR Newswire.
All rights reserved